Estonja - Estonjan - Ravimiamet

fatro s.p.a. - marbofloksatsiin - süstelahus - 40mg 1ml 250ml 1tk; 40mg 1ml 100ml 1tk; 40mg 1ml 50ml 1tk

Estonja - Estonjan - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+500mcg 1annus 60annus 1tk; 50mcg+500mcg 1annus 60annus 10tk; 50mcg+500mcg 1annus 60annus 2tk

Estonja - Estonjan - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+100mcg 1annus 60annus 1tk; 50mcg+100mcg 1annus 60annus 2tk; 50mcg+100mcg 1annus 60annus 10tk; 50mcg+100mcg 1annus 60annus 3tk

Estonja - Estonjan - Ravimiamet

zentiva k.s. - salmeterool+flutikasoon - annustatud inhalatsioonipulber - 50mcg+250mcg 1annus 60annus 3tk; 50mcg+250mcg 1annus 60annus 1tk; 50mcg+250mcg 1annus 60annus 10tk

Estonja - Estonjan - Ecolab

ecolab deutschland gmbh -

Estonja - Estonjan - Ravimiamet

dopharma research b.v. - tilmikosiin - lahus joogivees/piimas manustamiseks - 250mg 1ml 5040ml 1tk

Estonja - Estonjan - Ravimiamet

dopharma research b.v. - flubendasool - suspensioon joogivees manustamiseks - 200mg 1ml 5000ml 1tk; 200mg 1ml 1000ml 1tk; 200mg 1ml 500ml 1tk

Estonja - Estonjan - Ravimiamet

virbac - eprinomektiin - kriipsulahus - 5mg 1ml 5000ml 1tk; 5mg 1ml 2500ml 1tk; 5mg 1ml 4500ml 1tk

Estonja - Estonjan - Ravimiamet

eurovet animal health b.v. - sulfametoksasool+trimetoprim - lahus joogivees manustamiseks - 100mg+20mg 1ml 5000ml 1tk; 100mg+20mg 1ml 1000ml 1tk

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.